Related Experiment Videos
Pivmecillinam in the treatment of childhood pyelonephritis
Insights
Pivmecillinam effectively treats acute pyelonephritis in children, particularly infections caused by Gram-negative bacteria like E. coli. This study highlights its value in pediatric urinary tract infections.
Area of Science:
- Pediatric Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Acute pyelonephritis is a significant pediatric infection.
- Gram-negative bacteria, especially E. coli, are common causative agents.
- Effective antibiotic management is crucial for preventing complications.
Purpose of the Study:
- To evaluate the efficacy of pivmecillinam in treating acute pyelonephritis in children.
- To assess the spectrum of pathogens involved in pediatric pyelonephritis.
- To determine the safety and effectiveness of pivmecillinam in this population.
Main Methods:
- Prospective study involving twenty children (mean age 4 years).
- Treatment with pivmecillinam at 25-40 mg/kg/day.
- Urine culture analysis to identify pathogens.
Main Results:
- Pivmecillinam eradicated infections caused by Gram-negative pathogens (E. coli, Klebsiella spp.).
- Successful treatment was observed in one case of S. saprophyticus infection.
- One reinfection occurred in a patient with a urological malformation.
- Pivmecillinam was ineffective against mixed Gram-positive flora.
Conclusions:
- Pivmecillinam is a valuable therapeutic option for pediatric pyelonephritis.
- The drug demonstrates high efficacy against common Gram-negative urinary pathogens.
- Further investigation may be warranted for mixed Gram-positive infections.
Abstract:
In a prospective study, twenty children with a mean age of 4 years were treated with pivmecillinam, 25 mg to 40 mg per kilogram body-weight and day, for acute pyelonephritis. Urine cultures yielded growth of E. coli in sixteen instances, Klebsiella spp. in two, S. saprophyticus in one and a mixed Gram-positive flora in one patient. All children fulfilled the diagnostic criteria for upper urinary tract infection. In all cases where Gram-negative pathogens were responsible, the infections were eradicated. One reinfection was registered in a child with a concomitantly discovered congenital urological malformation. Pivmecillinam also cured one patient infected with S. saprophyticus but was ineffective in the case of mixed Gram-positive flora. It is concluded that pivmecillinam is a valuable new drug for the management of pyelonephritis in children, as most of these infections are caused by Gram-negative organisms.